ArticlePLoS computational biology2026
Interpretable neural networks prioritize cancer driver genes from genome-wide dependency landscapes.
Article in PLoS computational biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Identifying cancer driver genes and their therapeutic impact remains a core challenge in computational cancer biology. We introduce xNNDriver and xAEDriver, two interpretable neural network frameworks that connect cancer mutations with genome-wide DepMap gene dependencies, pathway activity, and drug-response patterns. xNNDriver is a supervised pathway-guided model that evaluates whether a gene's mutation status is encoded in the genome-wide dependency landscape; we interpret model fitness as a driver potential score, which quantifies the strength of this mutation-dependency signal and prioritizes genes with broad functional footprints. Across 3,008 candidate genes, xNNDriver recovers major established drivers and highlights literature-supported candidates, while pathway analyses reveal biologically coherent programs related to metabolism, growth factor signaling, and immune regulation. To capture combinatorial functional states, xAEDriver uses an unsupervised autoencoder to learn Driver Variant Representations (DVRs), latent binary features guided by the frequency distribution of known driver mutations. DVRs capture cell-line-specific dependency patterns and expression patterns and are associated with drug sensitivity and pathway activity. Together, these interpretable deep learning models demonstrate that gene dependency landscapes encode rich, interpretable signals of oncogenic function and provide a hypothesis-generating framework for prioritizing drivers, pathways, and therapeutic vulnerabilities for further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.